Ferroportin downregulation promotes cell proliferation by modulating the Nrf2–miR-17-5p axis in multiple myeloma

Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-mir-17-92

(2018) Eugenio Morelli et al.   BLOOD

The Roles of NRF2 in Modulating Cellular Iron Homeostasis

(2017) Michael John Kerins et al.   ANTIOXIDANTS & REDOX SIGNALING

Effects of Ferroportin-Mediated Iron Depletion in Cells Representative of Different Histological Subtypes of Prostate Cancer

(2017) Zhiyong Deng et al.   ANTIOXIDANTS & REDOX SIGNALING

MiR-148a participates in the growth of RPMI8226 multiple myeloma cells by regulating CDKN1B

(2016) Tao Lang et al.   BIOMEDICINE & PHARMACOTHERAPY

Decreased Ferroportin Promotes Myeloma Cell Growth and Osteoclast Differentiation

(2015) Zhimin Gu et al.   CANCER RESEARCH

Disordered signaling governing ferroportin transcription favors breast cancer growth

(2015) Yue Chen et al.   CELLULAR SIGNALLING

Fimbrial Cells Exposure to Catalytic Iron Mimics Carcinogenic Changes

(2015) Debora Lattuada et al.   INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Analysis ofHFEmutations and non-HFEgene mutations (TFR2andSLC40A1) in patients with phenotypic hemochromatosis from the basque country

(2015) A. Castiella et al.   International Journal of Laboratory Hematology

Nramp1 and Other Transporters Involved in Metal Withholding during Infection

(2015) Marianne Wessling-Resnick   JOURNAL OF BIOLOGICAL CHEMISTRY

miR-20a regulates expression of the iron exporter ferroportin in lung cancer

(2015) Kamesh R. Babu et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Improved risk stratification in myeloma using a microRNA-based classifier

(2013) Ping Wu et al.   BRITISH JOURNAL OF HAEMATOLOGY

Structure-Function Analysis of the Human Ferroportin Iron Exporter (SLC40A1): Effect of Hemochromatosis Type 4 Disease Mutations and Identification of Critical Residues

(2013) Gérald Le Gac et al.   HUMAN MUTATION

Iron Deprivation in Cancer––Potential Therapeutic Implications

(2013) Jessica Heath et al.   Nutrients

MiR-15a, miR-16-1 and miR-17-92 cluster expression are linked to poor prognosis in multiple myeloma

(2012) Xiao Gao et al.   LEUKEMIA RESEARCH

miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma

(2011) Lijuan Chen et al.   CANCER LETTERS

An Iron Regulatory Gene Signature Predicts Outcome in Breast Cancer

(2011) L. D. Miller et al.   CANCER RESEARCH

Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients

(2010) A. Broyl et al.   BLOOD

Two to Tango: Regulation of Mammalian Iron Metabolism

(2010) Matthias W. Hentze et al.   CELL

Heme controls ferroportin1 (FPN1) transcription involving Bach1, Nrf2 and a MARE/ARE sequence motif at position -7007 of the FPN1 promoter

(2010) S. Marro et al.   HAEMATOLOGICA

miRNAs in human cancer

(2010) Thalia A Farazi et al.   JOURNAL OF PATHOLOGY

High-risk myeloma is associated with global elevation of miRNAs and overexpression ofEIF2C2/AGO2

(2010) Yiming Zhou et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Ferroportin and Iron Regulation in Breast Cancer Progression and Prognosis

(2010) Z. K. Pinnix et al.   Science Translational Medicine

Deciphering the transcriptional circuitry of microRNA genes expressed during human monocytic differentiation

(2009) Sebastian Schmeier et al.   BMC GENOMICS

Role of iron in carcinogenesis: Cancer as a ferrotoxic disease

(2009) Shinya Toyokuni   CANCER SCIENCE

A Ferroportin Transcript that Lacks an Iron-Responsive Element Enables Duodenal and Erythroid Precursor Cells to Evade Translational Repression

(2009) De-Liang Zhang et al.   Cell Metabolism